Search research articles
Contact Us
Filters
Showing results (111-120 of 131) with videos related to
Page
of 14
Sort By:
Journal of Clinical Pharmacology
|
September 29, 2020
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects
Ariel R Topletz-Erickson, Anthony J Lee, JoAl G Mayor, et al.
Bioconjugate Chemistry
|
September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
Michael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Journal of Shoulder and Elbow Surgery
|
July 23, 2022
Outcomes and complications of primary reverse shoulder arthroplasty with minimum of 2 years' follow-up: a systematic review and meta-analysis
Joseph W Galvin, Ryan Kim, Alexander Ment, et al.
Biochemical Pharmacology
|
October 6, 1999
Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent
D L Walker, J M Reid, P A Svingen, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F McDonagh, Kristine M Kim, Eileen Turcott, et al.
Bioconjugate Chemistry
|
January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
Svetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Molecular Cancer Therapeutics
|
August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
The Journal of Clinical Investigation
|
July 15, 2025
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
Fernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira, et al.
Blood
|
January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Hans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylation
Nicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 131) with videos related to
Sort By:
Page
of 14
Journal of Clinical Pharmacology
|
September 29, 2020
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects
Ariel R Topletz-Erickson, Anthony J Lee, JoAl G Mayor, et al.
Bioconjugate Chemistry
|
September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
Michael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Journal of Shoulder and Elbow Surgery
|
July 23, 2022
Outcomes and complications of primary reverse shoulder arthroplasty with minimum of 2 years' follow-up: a systematic review and meta-analysis
Joseph W Galvin, Ryan Kim, Alexander Ment, et al.
Biochemical Pharmacology
|
October 6, 1999
Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent
D L Walker, J M Reid, P A Svingen, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F McDonagh, Kristine M Kim, Eileen Turcott, et al.
Bioconjugate Chemistry
|
January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
Svetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Molecular Cancer Therapeutics
|
August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
The Journal of Clinical Investigation
|
July 15, 2025
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
Fernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira, et al.
Blood
|
January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Hans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylation
Nicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Page
of 14